Protein Degrader Drugs Target Previously Untreatable Cells
New medical treatments are commandeering the cell's natural recycling system to eliminate harmful disease-causing proteins.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you trust that massive pharmaceutical investment in new drug classes will ultimately benefit patients?
Pharmaceutical companies are increasingly utilizing protein degrader drugs to target disease proteins that were once considered impossible to treat with traditional medicine. The FDA has recently authorized new therapies, including Veppanu and Zenbexus, to address specific cancers.
Why it matters
Researchers aim to broaden the range of treatable conditions by targeting the 85% of disease drivers that current traditional medicine cannot reach. This emerging therapeutic class leverages cellular waste disposal mechanisms to eliminate proteins that trigger disease.
Approximately 85% of disease-driving proteins are currently untreatable by traditional medicine. There are currently 200 protein degraders under study worldwide.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
Bristol Myers Squibb
This global biopharmaceutical company focuses on discovering and developing innovative medicines to help patients prevail over serious diseases.
Pfizer
Pfizer is a multinational pharmaceutical and biotechnology corporation that researches and develops vaccines and medicines.
Arvinas
Arvinas is a clinical-stage biopharmaceutical company focused on developing therapies that degrade disease-causing proteins.
Rigel Pharmaceuticals
Rigel is a biotechnology company focused on the discovery and development of novel small-molecule drugs for hematologic and oncologic diseases.
The details
Protein degraders and molecular glues function by binding a disease protein with an enzyme that disposes of cell waste, effectively hijacking the cell's own recycling system. Recent clinical developments include the use of mezigdomide, which extended disease-free survival to 18 months in multiple myeloma patients compared to 8 months for existing treatments.
Timeline
1950s: Thalidomide is developed.
1998: Protac technology is discovered.
2021-2026: Over $5 billion in deals occur for protein degrader drugs.
May 2026: The FDA approves Veppanu and mezigdomide results are released.
August 2026: The FDA approves the multiple myeloma treatment Zenbexus.
The Big Picture
The current wave of FDA-approved protein degraders represents the clinical maturation of the foundational research established by the 1998 Protac discovery.
These therapies offer new options for patients with specific genetic mutations, such as those with breast cancer and ESR1 mutations, who previously lacked targeted treatment. Patients should consult their oncologists to determine if these emerging, highly specific protein degrader therapies are appropriate for their unique molecular profile.
The takeaway
Protein degraders represent a significant shift from inhibiting disease proteins to physically destroying them within the cell. Patients and providers should watch for ongoing trial results that could expand the use of these drugs to a wider array of previously undruggable conditions.
What happens next
BeOne Medicines expects to report trial results for its BTK protein degrader in 2028, followed by Nurix Therapeutics in 2029.
Further reading
For additional context on oncological advancements, visit the United States Cancer section.
Source note: This article includes information reported by Hindustan Times.
Live Poll
Do you trust that massive pharmaceutical investment in new drug classes will ultimately benefit patients?
